Imaging Alzheimer's disease pathophysiology with PET

Area of Science:

• Neuroscience
• Medical Imaging
• Pharmacology

Background:

• Alzheimer's disease (AD) is now understood as a progressive condition with preclinical, mild cognitive impairment (MCI), and dementia stages.
• Molecular imaging, particularly Positron Emission Tomography (PET), offers insights into dementia pathophysiology.

Purpose of the Study:

• To highlight the significant contributions of PET molecular imaging in characterizing brain abnormalities in Alzheimer's disease.
• To emphasize PET's role in the shift towards early diagnosis and disease-modifying interventions for AD.

Main Methods:

• Utilizing various molecular imaging agents with Positron Emission Tomography (PET).
• Analyzing PET data to reveal aspects of dementia pathophysiology including amyloidosis, tau accumulation, neuroreceptor changes, metabolism, and neuroinflammation.

Main Results:

• PET imaging effectively visualizes key pathological hallmarks of Alzheimer's disease in the brain.
• PET allows for the quantification of AD pathophysiological processes and monitoring of disease progression.

Conclusions:

• PET molecular imaging is crucial for understanding Alzheimer's disease at a molecular level.
• PET facilitates early diagnosis, disease monitoring, and assessment of therapeutic efficacy in AD clinical trials.